Asset
PEMIGATINIB
Revenue
No revenue reported in loaded filings.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03235570 | phase1 | completed | 2017-08-01 | 2020-03-04 | Incyte Corporation | A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102) |
| NCT03011372 | phase2 | completed | 2017-04-25 | 2024-10-30 | Incyte Corporation | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) |
| NCT02872714 | phase2 | completed | 2017-01-12 | 2022-02-01 | Incyte Corporation | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) |
| NCT03656536 | phase3 | terminated | 2019-06-03 | 2025-07-07 | Incyte Corporation | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma |
| NCT04003623 | phase2 | terminated | 2019-10-31 | 2020-06-12 | Incyte Corporation | Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208) |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 213736 | NDA | INCYTE CORP |
Marketed products (3)
- PEMAZYRE
- PEMAZYRE
- PEMAZYRE